Bayer (BAYN) Stock Overview
Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BAYN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.75 |
| 52 Week High | €41.28 |
| 52 Week Low | €32.75 |
| Beta | 0.93 |
| 1 Month Change | -17.64% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -83.63% |
| 5 Year Change | -68.51% |
| Change since IPO | 33.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -14.5% | -5.5% | -5.3% |
| 1Y | n/a | 19.5% | 0.6% |
Return vs Industry: Insufficient data to determine how BAYN performed against the Swiss Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how BAYN performed against the Swiss Market.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.7% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: BAYN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine BAYN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 87,280 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market cap | CHF 33.53b |
| Earnings (TTM) | -CHF 3.27b |
| Revenue (TTM) | CHF 41.21b |
Is BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €45.58b |
| Cost of Revenue | €18.53b |
| Gross Profit | €27.05b |
| Other Expenses | €30.67b |
| Earnings | -€3.62b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 12, 2026
| Earnings per share (EPS) | -3.68 |
| Gross Margin | 59.35% |
| Net Profit Margin | -7.94% |
| Debt/Equity Ratio | 139.3% |
How did BAYN perform over the long term?
See historical performance and comparisonDividends
Does BAYN pay a reliable dividends?
See BAYN dividend history and benchmarks| Bayer dividend dates | |
|---|---|
| Ex Dividend Date | Apr 27 2026 |
| Dividend Pay Date | Apr 29 2026 |
| Days until Ex dividend | 48 days |
| Days until Dividend pay date | 50 days |
Does BAYN pay a reliable dividends?
See BAYN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 05:56 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bayer Aktiengesellschaft is covered by 39 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Emily Field | Barclays |
| Charles Pitman | Barclays |